share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Smither John W

SEC announcement ·  Feb 15 18:28
Summary by Moomoo AI
Arcutis Biotherapeutics, Inc. (ARQT) reported that its Chief Financial Officer, John W Smither, acquired a total of 11,365 shares of common stock on February 13, 2024. The transactions were classified as 'A' for acquisition under the transaction code, indicating they were likely grants or awards. Following these acquisitions, Smither directly holds 11,365 shares. Additionally, it was disclosed that Smither indirectly holds 141,392 shares of Arcutis Biotherapeutics common stock through a trust.
Arcutis Biotherapeutics, Inc. (ARQT) reported that its Chief Financial Officer, John W Smither, acquired a total of 11,365 shares of common stock on February 13, 2024. The transactions were classified as 'A' for acquisition under the transaction code, indicating they were likely grants or awards. Following these acquisitions, Smither directly holds 11,365 shares. Additionally, it was disclosed that Smither indirectly holds 141,392 shares of Arcutis Biotherapeutics common stock through a trust.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more